Nosopharm is an innovative biotechnology company headquartered in Lyon (France) and specialized in the research and development of new molecules to combat antimicrobial resistance (AMR). The mission of Nosopharm is to discover and develop novel first-in-class anti-infectives addressing unmet medical needs. The innovative anti-infective drug discovery platform developed by Nosopharm is based on the therapeutic exploitation of a very original bioresource: the bacterial genera Xenorhabdus and Photorhabdus. Anti-Infectives, Drug Discovery, Antibiotics, and Microbiology

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developpment of small molecules to prolong the protective effect of the Integrated Stress Response InFlectis BioScience is a private clinical-stage company aiming to target and modulate interactions between proteins involved in key human pathophysiological processes. The company is developing IFB-088 (INN: icerguastat), which specifically targets the Integrated Stress Response (ISR). Exploiting the ISR’s natural defense offers tremendous potential for the development of a new class of therapies. Led by InFlectis, this area of research is rapidly advancing, resulting in new treatments under development for a variety of diseases affecting the central nervous system (CNS), peripheral nervous system (PNS) and inflammation. …

109 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

ATOXIGEN is your partner in early R&D. We offer a variety of standardized or customized assays based on the latest innovations in the fields of cellular biology, molecular biology and genomics. Innovative predictive efficacy assays on reconstructed epidermis or primary cell lines from human explants (proteasome, autophagy, detoxification, anti-ageing...); in vitro genotoxicity testing (micronucleus and chromosome aberration tests); endocrine disruptor screening; customized services. Biotechnologies, Testing & Research, Evaluation toxicologique, and Assurance qualité

211 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Off-the-shelf precision vaccines to prevent deaths from cancer metastases Infinitopes is a pioneer in precision immunomics medicines. A Cancer Research UK (CRUK)-led biotech spinout from Oxford University, we are empowering the immune system to fight cancer metastases with unique, de novo antigen discovery technologies, innovative high efficiency vectors and intelligent clinical trial design. Our mission is to significantly enhance patient survival.

150 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

InnaVirVax is a French privately-owned biopharmaceutical company dedicated to the development of a cutting edge discovery in the field of therapy/prevention and prognostic of AIDS and HIV infection, other infectious diseases, and cancer therapies. InnaVirVax is developing product candidates resulting from a beakthrough discovery, made at Inserm, the French Medical research council, the AP-HP, the largest hospital in Europe, and University Pierre et Marie Curie in Paris. Based on a new paradigm (i.e. the understanding of the mechanism responsible for the decline of the CD4+ T lymphocytes (CD4) in HIV-infected patients), the products currently developed by InnaVirVax will allow the …

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Clinical stage biotechnology company whose vision is to be a trusted and acknowledged leader in the microbiome field. Da Volterra is a clinical stage biotechnology company whose vision is to be a trusted and acknowledged leader in the microbiota field. Our mission is to discover, develop and bring to market safe and novel therapeutic options, preserving patients’ microbiota to prevent and cure life-threatening diseases. We strive to serve patients by transforming the promise of science into innovative treatments which have the power to improve health and save lives.​ Committed to innovation, Da Volterra develops products intended to protect the intestinal …

89 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Developing tomorrow's cancer therapies. Today. invIOs is a private biotech company focusing on discovery and development of novel cancer therapeutics that empower and educate the immune system to fight cancer. We leverage our deep expertise in immune-system activation to advance a focused pipeline of individualized and targeted approaches against solid tumors. Our focus is on earlier-stage development, with a sweet spot in bringing assets through discovery and pre-clinical development and into clinical trials. We launched in 2022 as a spin-out bundling the innovative oncology assets of APEIRON Biologics. Our highly motivated team of 35 people has deep expertise across the …

372 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Eveliqure Biotechnologies is developing novel vaccines for the prevention of diarrhoeal diseases. Eveliqure Biotechnologies is an innovative biotech company developing novel vaccines for the prevention of diarrhoeal diseases both for travellers and people living in endemic regions of low- and middle-income countries. Eveliqure is a game-changer amongst vaccine companies, championing novel technologies to make the world safe from diarrhoea. Eveliqure is passionate about improving the quality of life for both the poor and the privileged by providing innovative medical solutions that fight diarrhoeal diseases.

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Laboratory for the Bioengineering of Tissues (Mixed Research Unit: Inserm and Bordeaux University) The BioTis laboratory (Laboratoire de Bioingénierie Tissulaire – Laboratory for the Bioengineering of Tissues) is a “Mixed Research Unit” (#1026) that is comprised of personnel from the INSERM, the French national institute of health and medical research), and from the University of Bordeaux. The Unit is located on the 5th floor of the new Bordeaux Biologie Santé (BBS) building at the University of Bordeaux medical campus. BioTis has around 65 members including full time researchers, junior and senior professors in medicine/medical sciences, technical and support staff, post-doc …

70 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Explore Understand Innovate LBTI is a leading French research laboratory specializing in the study of healthy and diseased tissues and in the development of innovative therapeutic strategies with high potential for translation toward clinical applications. We have strong expertise in human skin, cartilage and mucosae. Our specific research aims are: > to analyze the basic mechanisms of tissue organization and homeostasis, and to identify potential therapeutic targets > to understand and model the tissue response to physiological or pathological stress (including mechanical stress and aging) > to develop novel therapeutic approaches for tissue repair and targeted delivery of therapeutic agents …

87 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Leading the Microbiome revolution Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWSTTM, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. We are evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections, and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in …

137 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Science to Transform Lives Immunocore is a leading T cell receptor (TCR) biotechnology company working to create first-in-class biological therapies to address unmet patient needs in oncology as well as infectious and autoimmune diseases. See our community guidelines: http://bit.ly/2kFA8hr Biotechnology, Cancer, Oncology, Infectious Diseases, Autoimmune Diseases, T Cell Receptor, Immunotherapy, ImmTAX, ImmTAC, ImmTAV, and ImmTAAI

267 similar entities Type: Startup Activities: deeptech hrtech biotech Technologies: Synthetic Biology

Why replace antibiotics when we can make them work better? AI matches the bacterial genome to an adjunct - Phages first Why replace antibiotics when we can make them work better? Resistance often doesn't mean an antibiotic is finished — it means it needs a partner. We are the AI infrastructure layer that finds that partner in minutes, not months - starting with phages. Our platform reads the bacterial genome of a resistant isolate and returns the adjunct most likely to restore the antibiotic's response — ranked, scored, and confirmed by the ordering laboratory before any clinical use. Minutes, not …

81 similar entities Type: Startup Activities: deeptech healthtech Technologies: A.I.

Vital new drugs for pandemic infections We acquire, develop and license innovative drugs to treat pandemic infections. We have expanded to develop a broader portfolio of new therapies to meet the rising burden of critical priority infectious disease. Based at Alderley Park in the North West of England, our work addresses unmet patient needs and will bring new portfolio of drugs into clinical trials to treat patients suffering from life-threatening infections. Pharmaceuticals, R&D, Antimicrobial Resistance, and Development

147 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Delivering the promise of radiopharmaceuticals to patients. PASSION FOR PRECISION. ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and …

118 similar entities Type: SMB Activities: manufacturing biotech deeptech Technologies: Synthetic Biology

We invent for life! At MSD - known as Merck & Co., Inc. in the United States and Canada, headquartered in Rahway, New Jersey - we are united by our purpose of harnessing the potential of science to save and improve lives around the world. For more than 130 years, we have provided hope through the development of important medicines and vaccines. We aspire to be the world's leading biopharmaceutical research company and are currently at the forefront of research into innovative health solutions to advance the prevention and treatment of human and animal diseases. We foster a diverse and …

237 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Let's Build Better Cells Together At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQureTM gene editing risk assessment services enable high-performance cell engineering and rigorous evaluation of editing outcomes, supporting confidence in therapeutic development. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we’ve been advancing cell engineering, shaping …

334 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Leadership in overcoming the antibiotic resistance crisis. BioVersys AG is a SIX listed (BIOV) clinical stage Swiss pharmaceutical company focusing on research and development of small molecules acting on novel bacterial targets with applications in antimicrobial resistance (AMR) and targeted microbiome modulation. With the company’s two in house technology platforms: i) TRIC and ii)Ansamycin chemistry, BioVersys develops novel, innovative antibacterial drugs, overcoming resistance and modulating the microbiome. By this means, BioVersys addresses the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. Our most advanced research and development programmes address nosocomial …

63 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Bringing People & Ressources Together The creation of Genbiotech, a spinoff of the Laboratoires Genévrier results of 15 years of strategic involvement in biotechnological research with one goal: to improve the quality of life of patients in the field of rheumatology, dermatology and aesthetic. We believe that tomorrow medicine needs to be dedicated and targeted to patients. We aim to improve existing treatments by using non invasive processes allowing local and sustained administration of biological and active molécules. The company, incepted in 1998, has currently a staff of 11 people and is located in Sophia Antipolis (South of France). For …

633 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Rebalancing the immune system, resolving inflammation. Drug candidates from our molecular platforms normalize the immune system by downregulating pro-inflammatory immune response and upregulating regulatory immune response. IMD-Pharma S.A.S is a french biotechnology company conducting research and development of innovative drug candidates for immune-related inflammatory diseases. Founded in 2016, IMD-Pharma is a company from the Laboratoire de Chimie de Coordination (CNRS) and the Centre de Physiopathologie de Toulouse Purpan (INSERM/CNRS/Université Toulouse III). immuno-modulation, anti-inflammatory drugs, chronic inflammatory diseases, Multiple Sclerosis, Rheumatoid Arthritis, dendrimers, monocyte rehabilitation, and psoriasis

73 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Creative Technologies for Efficient Therapeutics, Precision medicine Inoviem Scientific is a private Bioanalytical company which delivers enabling information to secure drug discovery programs and to take informed decision by closing the gap between preclinical and clinical development. We reconcile translational pharmacology and human physiology by using fresh patient material from the target cohort, embracing the complexity of human diseases. Inoviem's enabling technologies are working in pathological conditions to get the treatment in development to the right patient. Our indication-agnostic access to patients combined with innovative label-free platforms deliver Target identification and validation, targets & Mode of Action deconvolution, patient stratification, …

196 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Make Visible the Invisible Faster to Make your World Safer Founded in 2014, DIAMIDEX (Diagnostic Microbiology Express) is an innovative company specialized in the detection and quantification of microorganisms of interest. Its mission: making the invisible visible faster, to make your world safer. Its patented innovative technological approach brings about a major breakthrough to meet the speed and technicality challenges arising from microbiological culture. Based on a powerful technological platform, recognized by the scientific and industrial communities, DIAMIDEX offers and develops turnkey test solutions, which can be used in both laboratories and in the field to obtain a quantitative count …

136 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

goes FAR BEYOND (Fighting Antimicrobial Resistance to the Biological EmergencY to Opportunistic and Neglected Diseases) Dimicare Biotech is a project from Université Côte d'Azur, INSERM and CNRS focused on the development of novel "precision" antimicrobial drugs to fight multidrug-resistant infections. Our main project focuses on the development of a new treatment against multidrug-resistant S. aureus strains (including the WHO priority MRSA; methicillin-resistance S. aureus strains). Currently, this treatment is in the early-preclinical phase where its efficacity against several clinical strains and its innocuity in Human cells has been confirmed. Dimicare Biotech is building a great team involving Microbiology Medical doctors, …

171 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Idea Therapeutics is a Spanish biotech start-up focused on advanced therapy medicinal products (ATMPs), aiming to address diseases with limited therapeutic options. Our current research projects focus on regenerative medicine and immunology, with a long-term vision of expanding into other high-impact therapeutic areas such as oncology. At Idea Tx, we believe in the transformative power of science. Our mission is to investigate and develop disruptive ideas into new research lines in the field of ATMPs. We follow an open innovation model through strategic partnerships with leading public and private hospitals and research centers, integrating the entire value chain and driving …

74 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Iterum Therapeutics plc is an Ireland-based clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives. These products are aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum’s first product is a novel anti-infective compound that has demonstrated potent in-vitro activity vs. a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. For more information on Iterum Therapeutics please visit www.iterumtx.com.

64 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Evolution. Adaptation. Future. Phage-based solutions to combat bacteria. - Prevention - Diagnosis - Treatment "One Health" personalized treatments. biotecnología, microbiología, investigación, biomedicina, bacteria, phage, and phage therapy

185 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Altevax is developing a disruptive immunotherapy technology against cancer Altevax is a Phase 2 clinical-stage biotechnology company developing a pioneering melanin-based immunotherapy platform for cancer treatment. Its patented technology enhances antigen-specific T-cell immune responses and is compatible with a broad range of peptides, with potential to complement existing immuno-oncology approaches, including anti-PD-1 therapies. Altevax’s lead program targeting TERT in glioblastoma is currently in Phase 2 clinical development. The company collaborates with leading clinical institutions, including AP-HP, and is actively fundraising and exploring strategic partnerships to accelerate development. Cancer vaccines, immunotherapy, melanin, therapeutic vaccines, Peptidic vaccines, infectious diseases, CD8 Killer T …

219 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Anything is Druggable - with Quantum Accuracy Qubit Pharmaceuticals brings unparalleled accuracy and precision to drug discovery and design, using quantum physics to develop life-changing treatments for major diseases. We leverage our technologies and expertise to advance 7 fully owned drug discovery programs focusing on cancer resistance and escapement, a growing concern in aging populations, and chronic inflammatory diseases. We also co-develop programs with academia and pharmaceutical partners. Our proprietary ATLAS drug discovery platform unites our technologies based on 30 years of research from renowned scientists and founders, Louis Lagardère (Sorbonne University and CNRS), Matthieu Montes (CNAM), Jean-Philip Piquemal (Sorbonne …

284 similar entities Tags: FrenchTech2030 Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Our mission for +25 years is to take care of people's health with an eye toward the future and innovation. We are moved by values ​​such as commitment, honesty and the desire to improve. Thanks to them and our team we have become the 3rd pharmaceutical laboratory that sells the most units in Spanish pharmacies. We are also pioneers in biosimilar drugs in Spain and Portugal and we also have a line of self-care products, sports nutrition under the Finisher brand and women's health under the Gynea brand. Our vocation to serve society means that we are always close to …

271 similar entities Type: SMB Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

From Microbes to One Health. Taylor made R&D to tackle infectious diseases. Vibiosphen is a SME healthcare biotechnology in infectious diseases founded in 2014. Given the important and interdependent human, animal, and environmental dimensions of antimicrobial resistance, the One Health concept promotes a global effort to achieve the best health for people, animals, and the environment. In this context, Vibiosphen takes part of the efforts that are underway to develop new anti-infective therapies, to rejuvenate the antibiotic pipeline, develop novel antibiotics, and discover innovative therapeutic strategies for priority pathogens. Based on its pluridisciplinary and integrated approaches, Vibiosphen, with more than …

63 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Molecular biology thought for your needs Biomnigene, a bioanalysis service company, helps prevent potential diseases and to authenticate, trace, secure, validate products and their effects through genetic analysis. Thanks to our expertise, we offer you integrated services for environmental, industrial (pharmaceutical, agro-food, cosmetic) or medical issues such as: - Analysis of the intestinal, skin, vaginal, pulmonary and soil microbiome (16S/ITS metagenomic, shotgun metagenomic, transcriptomic, WGS...). - Identification, quantification and authentication, monitoring of species in a pure sample and in a mixture (microorganisms, viruses, bacteria, meat, fish). - Genotyping - Antibody sequencing and safeguarding of hybridoma lines of special interest; - …

197 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Antineo aims to accompany customers in the preclinical development of novel anticancer agents. We provide services and strategic advice for preclinical development, optimal choice of in vitro and in vivo models as well as strategic input on potential indications to target in the therapeutic landscape. Développement préclinique, in vitro, ex vivo, in vivo, Preuve de concept, Expertise scientifique en pharmacologie, and Modèles à façon

223 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Fabentech is a privately owned biopharmaceutical SME based in Lyon (France) and created in 2009, which develops immunotherapies to address situations of emergency. In an environment where the globalization of trade accelerates the spread of epidemics and where the geopolitical context increases the risk of bioterrorist attacks, nations should be prepared to address various situations of public health & medical emergency. However, there is generally no real therapeutic option to fight acute symptoms arising from these neglected indications. Based on its horse F(ab’)2 platform, a fully-derisked technology in-licensed from Sanofi Pasteur, Fab’entech aims to provide therapeutic solutions in the fields …

106 similar entities Type: Startup Activities: biotech deeptech healthtech manufacturing Technologies: Synthetic Biology

Medincell is a pharmaceutical company at commercial stage. We develop a portfolio of long-acting injectables in various therapeutic areas. Our proprietary technology BEPO® aims to ensure patient compliance, improve the effectiveness and accessibility of treatments, and reduce their environmental footprint. We collaborate with tier-one pharmaceutical companies and foundations to improve Global Health through new therapeutic options. Our mission is to contribute to the improvement and protection of the health of populations across the world. The fair sharing of the value created with all our employees is the foundation of our business model. The sustainability of MedinCell is an essential condition …

577 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Texcell is a viral safety expert with roots dating back to 1987. Our work sits where science meets urgency. About Texcell We are a specialized CRO supporting biologics, vaccines, medical devices, cell and gene therapies, and other complex biological products. Our core expertise includes viral safety, viral clearance, biosafety testing, custom cell culture, cell banking support, and bioassays. For more than 30 years, clients have trusted Texcell for scientific rigor, responsive partnership, and practical support when programs need clarity. We design studies, solve technical questions, assess product safety, and move development programs forward with confidence. Our services include: Viral safety …

94 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

LinKinVax aims at creating a universal, safe, enduring, vaccines platform against multiple pathogens. We are a clinical stage Biotech Spin-off of the Vaccine Research Institute in France with a unique "DC targeting" platform covering infectious desaeses and oncology.

133 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Building a sustainable sector and accelerate the discovery of new treatments tailored to each patient. French consortium to develop new experimental models of cancer in 9 cancer pathologies of interest (Lung, Pancreas, Breast, Liver, Ovary...) 3 major R&D axes: - Developing in vivo models and cell-based assays - Mimicking the human biology by humanizing the tumor microenvironment in mice - Studying the microbiota in cancer patients Oncology, Cancer research, Patient derived Xenograft, Cell lines, Ex vivo assays, Microbiota, Data mining , Translationnal medecine, Humanized mice, Biomarker, Research and Development, In vivo models, Ex vivo models, and Cancer

264 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Reducing the gap between Lab and Clinical Trials with Physiological and Pathological Non-Animal Models Unique R&D platform of donor-derived real human adipose tissue ex vivo models for pharmaceutical drug development (obesity, chronic metabolic diseases), dermo-cosmetic, nutraceutical, aesthetic and reconstructive surgery research. ExAdEx-Innov owns exclusive worldwide rights to ExAdEx patented breakthrough technology to develop preclinical models derived from human adipose tissue obtained from patients. These models maintain their native 3D structure, stem cells, functionality, and vascularization over the long term in culture, providing a faithful representation of clinical conditions. They enable the pharmaceutical industry to generate reliable human data in the …

74 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Veterinary diagnostic testing evolution, innovation, research and solutions MI:RNA Diagnostics have developed a novel early disease detection technology for the veterinary market that uses microRNA biomarkers to accurately identify if disease is present, through blood sample analysis. By combining this method with an artificial intelligence learning model to enable interpretation, they have adopted a true precision medicine approach. Paving the way, they hope, for many other innovative solutions in this field. It is their mission to reduce disease through research and innovation, resulting in a cascade of ethical, environmental, and economic benefits.

203 similar entities Type: SMB Activities: pettech deeptech biotech Technologies: Data Analytics Synthetic Biology

At the forefront of the fight against antibioresistant bacteria Pherecydes Pharma develops antibacterial treatments based on the use of bacteriophage viruses, or phages, to fight bacterial infections in humans, particularly those resistant to antibiotics. Phages are natural predators of bacteria and have no demonstrated effect on eukaryotic cells, including human cells. Antimicrobial resistant bacteria or AMR are responsible for over 700,000 death a year in 2014 according to the WHO. This number might reach over 10,000,000 by 2050 if nothing is done, and no new class of antibiotics has been discovered in the last 30 years. Phages represent one of …

60 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

An innovative drug discovery technology Good morning and welcome, we are pleased to introduce you to our structure. AZELEAD has developed ZebraScreen and ZebraTox, an innovative methodology for rapid and accurate assessment of the efficacy and toxicity of a drug In the past few years, we have seen a lot of attrition in the development of new drugs, with a failure rate of nearly 84% attributed to the low benefit of efficacy / toxicity. Three therapeutic areas are mainly affected by this decrease:  oncology (failure rate of 29.5%),  neurology (failure rate of 14%),  and infectious diseases (failure …

283 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Our vision is to harness the power of the immune system to develop novel therapies against cancer & infectious diseases. Biopharmaceutical New Technologies (BioNTech) is a global biotechnology company aspiring to translate science into survival by developing new immunotherapies utilizing the full potential of the immune system to fight cancer and infectious diseases. BioNTech is headquartered in Mainz, Germany, and operates globally with almost 7.000 pioneers. Our work is powered by one mission: Improving the health of people worldwide. We believe that scientific rigor and passion are the driving forces that are essential for innovative progress. BioNTech was founded in …

270 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Eurofins Discovery offers you a complete, single-source solution for drug discovery products and services. Eurofins Discovery has supported Drug Discovery research for >40 years. Our partners inspire us to innovate in the pursuit of life-changing cures. We provide our experience, depth, and breadth in the form of innovative testing services and product tools that support researchers as they accelerate the discovery and development of candidate molecules. Our global team of dedicated scientists, information analysts, and client support professionals make this mission possible. Our focus drives us to continually expand our portfolio of testing methods, tools, and services to enable real, …

382 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing precision small molecules to combat hard-to-treat tumors. iOnctura is a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers with precision oral small molecules that target cancers in novel ways. The bold new treatments extend lives and improve healthspans, changing the outlook for patients and their families. Two therapeutic candidates have progressed into mid-stage clinical development: roginolisib is the first allosteric modulator of PI3Kδ and cambritaxestat is the only autotaxin inhibitor in clinical development to treat cancer. oncology, drug development, and clinical development

205 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Building on our impossible firsts, we can change the course of human health. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. RNA-targeted medicines and RNA-targeted …

63 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

AB Science was founded in 2001 by a team of researchers, clinicians and entrepreneurs who have dedicated their lives to discover key mechanisms in life science and develop new drugs targeting these mechanisms to dramatically change the life of patients in the most unmet medical needs. We are innovators and scientific entrepreneurs in the field of life science. Our group is specialized in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical needs in the field of cancers, chronic inflammatory diseases and neurological degenerative disorders. Our pipeline is both in Human and Veterinary medicine. Our drugs are …

370 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

TO DATE, THE MOST ADVANCED THERAPEUTIC AIDS VACCINE IN THE WORLD BIOSANTECH, created in April 2011 by Roger and Corinne TREGER, is an innovative company with an equitable NORTH/SOUTH vocation based in Sophia Antipolis Valbonne in the Provence-Alpes Cote d’Azur region. BIOSANTECH aims to promote and develop a vaccine effective against all variants of the AIDS virus. BIOSANTECH has an exclusive cooperation agreement with the CNRS and the University of Aix Marseille and is the owner of the exclusive license for the valorization and marketing of vaccine patents from “TAT Oyi”​. BIOSANTECH, to date, has the only therapeutic vaccine in …

58 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Transforming lives with groundbreaking treatments Coultreon Biopharma's mission (formerly Onco3R Therapeutics) is to develop life-changing medicines for patients affected by chronic inflammatory diseases of high unmet medical needs. The team is leveraging their knowledge and expertise to bring transformative innovations to patients suffering from auto-immune diseases. In this field, there is an urgent need for more convenient oral drugs that can offer greater efficacy with a better safety profile. Drug Discovery, Drug Development, Immunology, Biotech, and R&D

826 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Innovative therapeutic procedures for Intensive Care Medicine for the treatment of severe infections / sepsis ARTCLINE GmbH develops innovative therapy methods for intensive care medicine based on immune cells. Our current main project is the development of the so-called ARTICE technology for the treatment of bacterial sepsis. ARTCLINE's vision is the development of innovative immune cell-based therapy approaches and to make the technology available to physicians and hospitals worldwide. The safety and effectiveness of the therapy is our top priority. Our extensive cell biological, clinical and industrial experience in the fields of immunology, sepsis diagnostics and therapy help us to …

94 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Bringing expertise and agility to biotech companies Founded in 2013 and headquartered in Montpellier, France, INITS is a pharmaceutical development and biomanufacturing services company supporting biotech and life sciences companies developing new therapeutic products. With more than 13 years of experience and over 250 clients supported in France and internationally, INITS provides expertise across biologics (cell and gene therapies, extracellular vesicles, antibodies and proteins) as well as small and large molecules. Its team of more than 40 experts supports the full range of pharmaceutical development activities, including CMC development, Regulatory Affairs, Clinical Supply, Quality Assurance and GMP audits. INITS is …

67 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Integrating talent, improving your quality of life The mission of the INCLIVA Health Research Institute is “To promote, promote, coordinate and execute quality research, integrating the basic and clinical aspects of the research process, with the aim of contributing to improving the health and quality of life of citizens.” Through the application of translational research, which ranges from laboratory studies to clinical trials, INCLIVA's vision is "to become a reference center at a national and international level in the prioritized fields of biomedical research, through management of excellence, which allows the optimization of the use of resources intended for the …

54 similar entities Type: SMB Activities: deeptech

A leading nationwide clinical research site network pursing life-changing therapies committed to better patient outcomes CenExel is a leading integrated, wholly owned, nationwide clinical research site network comprised of 18 Centers of Excellence in major metropolitan areas across the U. S. With 40+ years of experience, our Centers of Excellence deliver deep scientific expertise, premium data, operational efficiencies, and exceptional patient engagement to drive successful complex clinical trial outcomes. The world's most results-driven Pharma, Biotech, and Clinical Research Organizations trust our strategic approach and benefit from our collaboration and unified sites’ commitment to real world solutions. Rely on us to …

131 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Our vision is to transform the lives of patients with curative therapies. Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT, STAT6 and MRGPRX2 inhibition. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens …

66 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Innovation for Biotherapies BIOSYNEX was founded in 2005 and is one of the most significant European manufacturers and provider of rapid membrane tests in the in-vitro diagnostic market. By staying close to our customers and business partners we are aware of the needs and expectations they may have of our products and services. Listening to their voice, together with the help of our Research and Development laboratories in France and our state of the art manufacturing facilities, allows us to identify new applications in rapid testing, develop and launch innovative products and provide high quality services. Our aim is to …

297 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Leading the creation of transformative, first-in-class anti-infectives for life-threatening respiratory infections Aridis Pharmaceuticals is a late-stage clinical development company leading the creation of transformative, first-in-class anti-infectives for life-threatening respiratory infections. The company’s pipeline of novel mechanism antibacterial and antivirals, sprung from its proprietary technology platforms, are designed to combat the growing public health threat of antimicrobial resistant bacteria (AMR). Monoclonal Antibody , Infectious Disease, Cell line Engineering, Inhalation therapy

147 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Science in Translation - We put inspiration into practice, finding viable solutions to complex challenges. Our mission is to turn scientific breakthroughs into progress for patients. TRON is a non-profit research institute that pursues new diagnostics and drugs for the treatment of cancer and other diseases with a high medical need. We aim to bridge the gap between fundamental science at universities and market-oriented research in the pharmaceutical industry. We turn innovative scientific concepts into treatments ready for clinical testing, thereby accelerating the translation of discoveries into new diagnostics and therapies for patients. We focus our transdisciplinary competencies in genomics …

180 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Innovating vaccines to reduce human diseases. Part of Utrecht Science Park Bilthoven Even the most promising vaccines don’t always make it out of the laboratory into large-scale production. We at Intravacc are fully aware of the challenges on the long road of vaccine development. We substantially reduce the risks and costs involved with developing vaccines. How? By bridging the gap between your concept and late stage clinical studies. As an established independent CDMO in the vaccine industry, Intravacc offers a wide range of expertise and is the bridge between your discovery and the start of your phase I/II clinical trials …

80 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Investing dark biodiversity DEINOVE is a French biotechnology company pioneering the exploration of a new domain of life, unexplored at 99.9%: the microbial dark matter. By revealing the metabolic potential of rare bacteria or still classified as uncultivable, it tackles a global health and economic challenge: antimicrobial resistance. The new therapies discovered and developed by DEINOVE (antibiotics, antifungals, antivirals and antiparasitics) target superbugs (microbes that resist to one or several antimicrobials) that cause life-threatening infections which are now spreading at high speed. This breakthrough approach gave birth to one of the World first specialized micro-biotechnology platforms and a unique collection …

72 similar entities Type: SMB Activities: biotech deeptech

Our Vision We aim at changing the way drug development research is done today by providing in-vitro models that reproduce the in-vivo environment in an unprecedented way. These in-vitro models, called organ-on-chips, will make it possible to better predict drugs’ responses in humans than standard in-vitro and in-vivo models and as a consequence to importantly reduce animal testing. Our Mission AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at improving preclinical decision-making and thus reducing drug development costs. Research, Innovation, Technology, In-vitro, 3D Cell Culture, Organ-on-Chip, Respiratory diseases, Drug Development, Drug Discovery, Preclinical Services, Safety, Efficacy, …

94 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Understanding biological complexity, from genotype to phenotype, with interdisciplinary approaches. Our laboratory is a joint research unit of INSERM and the University of Aix-Marseille. We seek to decipher the complex biological mechanisms involved in the development or physiological functioning of an organism. Our research project is organized around two axes, one entitled "bioinformatics and genomics of molecular networks", the second "genetics and genomics of multifactorial diseases". We conduct not only basic research projects, but also collaborative projects with hospitals and biotech companies. This policy is fully in line with INSERM's strategic plan. Our ambition is both to contribute to a …

105 similar entities Type: SMB Activities: deeptech Technologies: Synthetic Biology

In-Cell-Art, is a biopharmaceutical company specializing in the preclinical and pharmaceutical development of solutions (DNA/RNA based vaccines or therapeutics) treating acquired or inherited diseases using patented bioinspired synthetic delivery systems (named Nanotaxi®) consisting of different chemical families (lipids, polymers). Its founder and research team, which includes a Nobel Laureate, have developed this unique intellectual property expertise and know-how based on 20 years of research in the field of supramolecular nucleic acids transfection agents. The vaccines and therapeutics developed by In-Cell-Art have been validated by numerous studies using infectious disease models (HIV, Flu, Dengue, dust mite, mycobacterium abscessus), therapeutic cancer models …

62 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Discovering & developing novel anti-infectives to treat multi-drug resistant bacterial & hard-to-treat viral infections. Venatorx Pharmaceuticals is a private pharmaceutical company that is focused on the discovery and development of novel anti-infectives to treat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections. antibiotics, antiinfectives, antivirals, drug development, drug discovery, pharmaceuticals, #battlesuperbugs, #WorkingToFightAMR, clinical, research, #squashsuperbugs, biotech, and antimicrobialresistance

91 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Powering Biomarkers from Discovery to Diagnostics Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognosis and precise treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used …

188 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Redefining the orphan drug landscape & unlocking energy for patients with rare diseases in Europe Founded by biopharmaceutical executives, Adam Plich and Anant Murthy, Avanzanite is on a mission to redefine the commercialization of orphan medicines to improve patient access across Europe and beyond. Derived from the word ‘Tanzanite’ – one of the rarest and most underappreciated gemstones on earth – Avanzanite was formed to capitalize on two primary objectives, one economic, and one humanitarian. The economic goal is to offer end-to-end commercialization and distribution partnerships with research-based biopharmaceutical originators to unlock the full value of their orphan medicines in …

82 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology